Maj Invest Holding A S Grows Stake in Johnson & Johnson (NYSE:JNJ)

Maj Invest Holding A S grew its holdings in Johnson & Johnson (NYSE:JNJ) by 18.7% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 794,595 shares of the company’s stock after acquiring an additional 125,295 shares during the quarter. Johnson & Johnson comprises 3.2% of Maj Invest Holding A S’s investment portfolio, making the stock its 18th biggest holding. Maj Invest Holding A S’s holdings in Johnson & Johnson were worth $116,136,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in JNJ. Norges Bank acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $4,071,642,000. Wellington Management Group LLP lifted its position in Johnson & Johnson by 16.4% during the 4th quarter. Wellington Management Group LLP now owns 24,019,725 shares of the company’s stock worth $3,764,852,000 after acquiring an additional 3,391,657 shares during the period. Price T Rowe Associates Inc. MD lifted its position in Johnson & Johnson by 16.8% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 21,834,359 shares of the company’s stock worth $3,453,978,000 after acquiring an additional 3,139,499 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Johnson & Johnson by 1.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 15,945,533 shares of the company’s stock worth $2,483,532,000 after buying an additional 241,799 shares in the last quarter. Finally, California Public Employees Retirement System raised its stake in shares of Johnson & Johnson by 4.9% during the 4th quarter. California Public Employees Retirement System now owns 10,620,264 shares of the company’s stock worth $1,664,620,000 after buying an additional 498,647 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.1 %

Shares of NYSE JNJ traded up $0.21 during midday trading on Wednesday, reaching $158.60. 1,820,741 shares of the company’s stock were exchanged, compared to its average volume of 7,333,679. Johnson & Johnson has a 52-week low of $143.13 and a 52-week high of $175.39. The stock has a market capitalization of $381.70 billion, a PE ratio of 9.89, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.85 and a current ratio of 1.07. The business’s fifty day moving average price is $151.63 and its two-hundred day moving average price is $153.06.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The business had revenue of $22.45 billion for the quarter, compared to analyst estimates of $22.33 billion. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The company’s revenue for the quarter was up 4.3% compared to the same quarter last year. During the same period in the previous year, the company earned $2.80 earnings per share. Analysts forecast that Johnson & Johnson will post 10.07 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.13%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is currently 30.92%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on JNJ shares. TD Securities dropped their price objective on Johnson & Johnson from $195.00 to $185.00 in a research note on Thursday, July 18th. Bank of America dropped their price objective on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, April 17th. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, August 5th. Royal Bank of Canada reissued an “outperform” rating and set a $175.00 price target on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Finally, Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Seven analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.